Yellow fever vaccine

Noreen A. Hynes, M.D., M.P.H., D.T.M.&H.
Yellow fever vaccine is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

VACCINE TYPE

General Identification

Live, attenuated yellow fever virus

Vaccine Strain Characteristics

  • The only approved vaccine for use worldwide is a live, attenuated virus derived from the original lot, 17D yellow fever virus strain, created by passing the wild-type virus repeatedly in cultures attenuate its virulent properties while ensuring it would induce immunity to the virus in the vaccine recipient.
    • There are two 17D strains in use today (with 99.9% sequence homology):[13]
      • 17D-204: found in the U.S. licensed vaccine (YF-VaxTM), and in StamarilTM which is produced in France and licensed in 44 non-U.S. countries.
      • 17DD: manufactured in Brazil
  • The attenuation process used minced chick embryo cultures (no brain or spinal cords included), and the final passage prior to human use was in embryonated eggs.
  • The vaccine comprises quasi-species as the vaccines are not plaque-purified and contain heterogeneous subpopulations with differing mouse-brain neurovirulence.

Non-Virus Constituents in the Vaccine

  • No antibiotics or preservatives are part of any yellow fever vaccine manufactured worldwide.
  • The vaccine is lyophilized for storage and must be reconstituted before use.
    • It must be administered within 60 minutes of reconstitution to ensure potency and to avoid bacterial contamination.
  • Manufacturer variability: salt, buffers, and stabilizer excipients.
    • Stabilizers are needed to maintain potency.
      • U.S. and U.K. (YF-VaxTM): sorbitol and porcine gelatin for stabilization.
      • France (StamarilTM): sugars, amino acids, and divalent cations for stabilization.

Viremia following 17D Yellow Fever Vaccination

  • 17D vaccine induces minimal virus titers in circulating blood instead of the high virus titers that were seen in natural yellow fever virus infection.
    • Similar onset to natural infection: ~ day 4 following inoculation, ends about neutralizing antibody appearance day 8 or 9 (see Immune Response below).
  • Vaccine titers are below the threshold for uptake by the mosquito virus vector of yellow fever.
    • Thought to explain the low risk of maternal-fetal transmission and low rates of neurotropic and viscerotropic vaccine adverse effects.

-- To view the remaining sections of this topic, please or --

VACCINE TYPE

General Identification

Live, attenuated yellow fever virus

Vaccine Strain Characteristics

  • The only approved vaccine for use worldwide is a live, attenuated virus derived from the original lot, 17D yellow fever virus strain, created by passing the wild-type virus repeatedly in cultures attenuate its virulent properties while ensuring it would induce immunity to the virus in the vaccine recipient.
    • There are two 17D strains in use today (with 99.9% sequence homology):[13]
      • 17D-204: found in the U.S. licensed vaccine (YF-VaxTM), and in StamarilTM which is produced in France and licensed in 44 non-U.S. countries.
      • 17DD: manufactured in Brazil
  • The attenuation process used minced chick embryo cultures (no brain or spinal cords included), and the final passage prior to human use was in embryonated eggs.
  • The vaccine comprises quasi-species as the vaccines are not plaque-purified and contain heterogeneous subpopulations with differing mouse-brain neurovirulence.

Non-Virus Constituents in the Vaccine

  • No antibiotics or preservatives are part of any yellow fever vaccine manufactured worldwide.
  • The vaccine is lyophilized for storage and must be reconstituted before use.
    • It must be administered within 60 minutes of reconstitution to ensure potency and to avoid bacterial contamination.
  • Manufacturer variability: salt, buffers, and stabilizer excipients.
    • Stabilizers are needed to maintain potency.
      • U.S. and U.K. (YF-VaxTM): sorbitol and porcine gelatin for stabilization.
      • France (StamarilTM): sugars, amino acids, and divalent cations for stabilization.

Viremia following 17D Yellow Fever Vaccination

  • 17D vaccine induces minimal virus titers in circulating blood instead of the high virus titers that were seen in natural yellow fever virus infection.
    • Similar onset to natural infection: ~ day 4 following inoculation, ends about neutralizing antibody appearance day 8 or 9 (see Immune Response below).
  • Vaccine titers are below the threshold for uptake by the mosquito virus vector of yellow fever.
    • Thought to explain the low risk of maternal-fetal transmission and low rates of neurotropic and viscerotropic vaccine adverse effects.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: July 4, 2021